𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

✍ Scribed by Scaltriti, M; Verma, C; Guzman, M; Jimenez, J; Parra, J L; Pedersen, K; Smith, D J; Landolfi, S; Ramon y Cajal, S; Arribas, J

Book ID
109970763
Publisher
Nature Publishing Group
Year
2008
Tongue
English
Weight
537 KB
Volume
28
Category
Article
ISSN
0950-9232

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Lapatinib, a dual HER1/HER2 tyrosine kin
Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth
✍ Alejandro Vazquez-Martin; Cristina Oliveras-Ferraros; Silvia CufΓ­; Sonia Del Bar πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 252 KB

## Abstract The ultimate biological and clinical meaning of shed HER2 extracellular domain (ECD) has remained largely unclear until recently. Oversecretion of soluble HER2 ECD has been shown to inhibit growth of HER2‐overexpressing cancer cells by promoting HER2 ECD dimerization with HER transmembr

Effects of the tyrosine-kinase inhibitor
Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced HER-2/NEU activation, receptor expression and proliferation of HER-2-positive malignant cell lines
✍ Frank Hartmann; Eva M. Horak; Cheryl Cho; Ruth Lupu; Joseph B. Bolen; Mary A. St πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 French βš– 408 KB πŸ‘ 2 views

Geldanamycin belongs to the family of benzoquinoid ansamycin tyrosine-kinase inhibitors. We have examined its effects on Her-2/neu kinase activity, protein expression level, and proliferation of Her-2+ malignant cells. In SK-BR-3 breast-cancer cells, short-time treatment with geldanamycin completely